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ABSTRACT—Acute trauma coagulopathy (ATC) is seen in 30% to 40% of severely injured casualties. Early use of blood
products attenuates ATC, but the timing for optimal effect is unknown. Emergent clinical practice has started prehospital
deployment of blood products (combined packed red blood cells and fresh frozen plasma [PRBCs:FFP], and alternatively
PRBCs alone), but this is associated with significant logistical burden and some clinical risk. It is therefore imperative to
establish whether prehospital use of blood products is likely to confer benefit. This study compared the potential impact of
prehospital resuscitation with (PRBCs:FFP 1:1 ratio) versus PRBCs alone versus 0.9% saline (standard of care) in a model
of severe injury. Twenty-four terminally anesthetised Large White pigs received controlled soft tissue injury and controlled
hemorrhage (35% blood volume) followed by a 30-min shock phase. The animals were allocated randomly to one of three
treatment groups during a 60-min prehospital evacuation phase: hypotensive resuscitation (target systolic arterial pressure
80 mmHg) using either 0.9% saline (group 1, n = 9), PRBCs:FFP (group 2, n = 9), or PRBCs alone (group 3, n = 6).
Following this phase, an in-hospital phase involving resuscitation to a normotensive target (110 mmHg systolic arterial
blood pressure) using PRBCs:FFP was performed in all groups. There was no mortality in any group. A coagulopathy
developed in group 1 (significant increase in clot initiation and dynamics shown by TEG [thromboelastography] R and K
times) that persisted for 60 to 90 min into the in-hospital phase. The coagulopathy was significantly attenuated in groups 2
and 3 (P = 0.025 R time and P = 0.035 K time), which were not significantly different from each other. Finally, the volumes
of resuscitation fluid required was significantly greater in group 1 compared with groups 2 and 3 (P = 0.0067) (2.8 T 0.3 vs.
1.9 T 0.2 and 1.8 T 0.3 L, respectively). This difference was principally due to a greater volume of saline used in group 1
(P = 0.001). Prehospital PRBCs:FFP or PRBCs alone may therefore attenuate ATC. Furthermore, the amount of
crystalloid may be reduced with potential benefit of reducing the extravasation effect and later tissue edema.
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INTRODUCTION
Trauma is the leading cause of death in the first four decades
of life in the developed countries (1, 2), and hemorrhage remains
one of the principal causes of death in both civilian and military
(battlefield) trauma (3Y5). Hemostasis is therefore a key determi-
nant for a patient_s survival both immediately after the trauma
and over the ensuing hours. Unfortunately a patient_s hemostatic
potential is impaired by the rapid development of a coagulopathy
associated with trauma.
Trauma-induced coagulopathy is now recognized as a seri-
ous secondary consequence of injury and the patient_s (patho)
physiological response to trauma (6Y8). Approximately one third
of seriously injured civilian casualties (9Y11) and potentially
similar proportions of military casualties (12, 13) are coagulo-
pathic by the time they arrive in hospital. Trauma-induced
coagulopathy has an evolving pathology in the patient, often
starting with the consequences of tissue hypoperfusion and de-
veloping through phases that can include the consequences of
shock-driven acidosis, hypothermia, iatrogenic (and autogenic)
hemodilution, and factor consumption (6, 8). Some authors also
suggest an element akin to diffuse intravascular coagulation,
without necessarily having tissue hypoperfusion (14). The study
reported in this article has targeted the early phase of trauma-
induced coagulopathy, associated with tissue hypoperfusion
and traumatic shock. This initial phase of trauma-related co-
agulopathy is referred to as acute trauma coagulopathy (ATC),
which manifests as attenuated coagulation early after injury
and is associated with tissue hypoperfusion. A number of studies
have shown that the presence of ATC is independently asso-
ciated with increased mortality, morbidity (e.g., organ failure),
duration of stay in the intensive care unit, and transfusion re-
quirement (9Y11).
The evolving understanding of the mechanism(s) of ATC has
to some extent driven therapy. Current therapy centers on early
and aggressive use of blood products such as plasma and fibrin-
ogen (6, 8) as well as red blood cells, with an emphasis on a high
ratio of plasma to red blood cells, whereas the use of colloids
and crystalloids is limited (15). However, our understanding of
ATC is far from complete, and resuscitation protocols are still
being developed and refined. Volume replacement that aug-
ments coagulation function using fresh frozen plasma (FFP),
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plasma concentrates, and packed red blood cells (PRBCs) is
currently one of the main strategies to treat ATC (6); indeed,
there is a long history of this practice in some US civilian hos-
pitals (16) as well as the more consistent drive arising from
recent military experience in Iraq and Afghanistan (8). While
permissive hypotension has become an established prehospital
resuscitation strategy, there is no clear evidence to guide the
type and volume of fluid that should be used (6). An empirical
approach of administering blood products as early as possible
has been adopted clinically. In the majority of cases, this in-
volved early and aggressive in-hospital use of blood products.
However, the UK MERT (Medical Emergency Response Teams,
UK military helicopter retrieval in Afghanistan) was able to pro-
ject FFP and PRBCs into the prehospital arena (17). By contrast,
civilian helicopter ambulance services in the United Kingdom
project PRBCs but no plasma into the prehospital arena
(M. Midwinter, personal communication, oral, 1 May 2015).
Since prehospital projection of PRBCs and FFP does have
significant logistical implications (e.g., ensuring appropriate
storage conditions and traceability) and some clinical hazards
(e.g., possible transfusion reactions and infection), especially in
austere circumstances, it is important to determine whether ear-
lier (prehospital) administration confers advantage compared
with immediate in-hospital administration. Furthermore, to aid
in the translation of military Blessons learned[ into the civilian
setting, it is important to compare the military (prehospital
PRBCs:FFP) and civilian (prehospital PRBCs alone) putative
Bbest practices[ to the original (often current) standard of care
(limited use of asanguineous fluid).
The aim of this study was to compare three treatments
(PRBCs:FFP, PRBCs alone, and 0.9% saline alone) for simu-
lated prehospital hypotensive resuscitation in a model of com-
plex injury involving both tissue injury and hemorrhagic shock.
The prehospital phase was followed by a simulated in-hospital
phase, which involved normotensive resuscitation in all cases
with PRBCs:FFP (1:1) ratio. The principal outcome variable was
coagulopathy assessed using thromboelastography (TEG) 30 min
into the in-hospital phase, corresponding to times when surgical
decisions are made, often based on the patient_s physiological
and coagulopathic state. Secondary outcomes included physio-
logical changes and volumes of the various fluids needed for
resuscitation, using current standard clinical endpoints based on
pressure-driven targets (18, 19).
MATERIALS AND METHODS
The study was conducted on terminally anesthetized cross-bred female
Large White pigs (43Y56 kg) and was ethically reviewed and conducted in
accordance with the Animals (Scientific Procedures) Act, 1986. The animals were
housed indoors and were fed on a complete diet comprising coarse ground mixture
of wheat, barley, soya protein, vitamins, and minerals. The animals fed ad libitum
and consumed approximately 5 kg/d. They were allowed water ad libitum.
Blood bank
Blood was collected by exsanguination from terminally anesthetised female
Large White pigs. Briefly standard units (1 U represents approximately 450 mL)
of blood were collected from a carotid cannula at a flow rate of 65 to 90 mL/min
into each CPD blood collection bag (RCB434CCL; Pall Medical, Portsmouth,
UK), with pauses between bag collection resulting in an overall bleeding rate of
22.5 mL/min. The blood was processed according to standard UK blood transfusion
protocols (20) to separate the red blood cells from the plasma, which was
leukodepleted, whereas the PRBCs were stored with SAG-M. The platelets
were discarded. Collected units of blood were processed within 90 min of
collection. The resulting units of PRBCs were stored at 4-C (LabCold Blood
Bank, Basingstoke, UK) and used within 14 days of collection. The plasma
(FFP) was fast-frozen (MP1100 Plasma Freezer System; Thermogenesis,
Noblesville, US), stored at j30-C (LabCold Plasma Freezer; LabCold), and
used within 6 months of collection. Fresh frozen plasma was thawed at 37-C
in a dry plasma thawer (Sahara III Maxitherm; Sarstedt, Nu¨mbrecht, Germany)
immediately before use. Prior to use, all donor products were forward and re-
verse matched to recipient blood. In addition, because PRBCs and FFP from
different donors were used for resuscitation, they were also cross-matched
with each other.
Surgical preparation
The animals were fasted for 18 h before the surgical procedure, but allowed
water ad libitum. After premedication with intramuscular midazolam hydro-
chloride (0.1 mg/kg), anesthesia was induced by mask with isoflurane (5%) in
a mixture of oxygen and nitrous oxide (1:1), and the animals intubated. Sur-
gical anesthesia was subsequently maintained with isoflurane (1%Y2%) in a
mixture of oxygen and nitrous oxide (1:2), and the animals ventilated using positive-
pressure ventilation (Blease Manley MP3 Anaesthesia Ventilator). Initial monitoring
consisted of end-tidal CO2, pulse oximetry through a tail probe, and skin surface
electrocardiogram electrodes (Propac 106EL; Protocol Systems Inc, Beaverton, Ore).
With the animal positioned supine, surgical preparation took place after skin
preparation with povidone-iodine solution (10% wt/vol, Betadine Aqueous
Antiseptic Solution; Seaton Healthcare Group plc, UK).
The left carotid artery (Swan Ganz; Edwards Lifesciences Ltd, Newbury,
UK), both internal jugular veins, and left femoral artery and vein were cannulated
(Portex 8FG; Sims Portex Ltd, Hythe, UK). A balloon-tipped flow-directed
cannula (744MF75 Swan Ganz; Edwards Lifesciences Ltd) was introduced
through a right internal jugular vein cannula introducer sheath (Desivalve Catheter
Introducer; Vygon, Cirencester, UK) and advanced until its tip was in the
pulmonary artery. Cannula placement was determined by monitoring pressure
changes at the tip.
After venous access had been established, anesthesia was continued with
intravenous alphaxalone to maintain a surgical plane of anesthesia assessed by
palpebral reflex and jaw tone (Alfaxan; Jurox (UK) Ltd, Malvern Link, UK),
and the isoflurane discontinued.
A midline laparotomy was performed, the spleen contracted by topical
application of adrenaline (up to 1.5 mL of a 1mg/mL solution) before removal,
and the bladder catheterized by open suprapubic cystostomy. All incisions were
closed en masse. Animals were allowed to breathe spontaneously for the
remainder of the experiment unless they displayed marked respiratory de-
pression, at which stage synchronized intermittent mandatory ventilation
(Drager Evita 2; Draeger Medical UK Ltd, Hemel Hempstead, UK) was in-
stituted in an attempt to maintain adequate oxygenation and prevent severe
hypercapnea. The animals recovered from surgery under anesthesia for 1 h
before baseline measurements were made.
Cardiovascular monitoring
Arterial blood pressure was recorded through the carotid artery cannula,
and pulmonary arterial and central venous pressures were recorded via the
flow-directed, balloon-tipped flotation catheter, which was also used to de-
termine cardiac output as a 6-min rolling average (Vigilance Volumetrics
CEDV; Edwards Lifesciences Ltd). Physiological pressure measurements were
made using strain gauge manometers (Sensonor 840; SensoNor a.s., Skoppum,
Norway), and zero pressure for all transducers was set at heart level. Body tem-
perature was maintained at approximately 38-C using external heating/cooling
and blankets as appropriate. The bladder was drained at hourly intervals.
All cardiovascular variables were recorded using a computerized data ac-
quisition system (Maclab 8/s; ADInstruments, Oxford, UK) and associated
software (Chart v4.2.3; ADInstruments) for subsequent analysis.
Blood gas and related chemistry
Arterial and venous blood samples were taken anaerobically into heparin-
ized syringes from the carotid and pulmonary artery catheters, respectively, for
blood gas, base excess, and lactate analysis (Gem Premier 3000 Blood Gas
Analyzer; Instrumentation Laboratories, Warrington, UK).
Experimental protocol
The animals were randomly allocated to one of three treatment groups at the
outset (Fig. 1). One hour after the end of surgery, three cardiovascular mea-
surements were made 5 min apart and paired arterial and mixed venous blood
gas samples taken at the time of the first and third baseline cardiovascular
measurement. The timeline for the experimental protocol is shown in Figure 1.
Injury phase—All animals were subjected to a controlled soft tissue injury
using a blunt captive bolt pistol (CASH Special Knocker; Accles & Shelvoke,
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Sutton Coldfield, UK) delivering four standard impacts (using 2 Grain .25
cartridges) to the muscle of the right hindquarter. This resulted in widespread
deep contusion in the underlying muscle but no fracture to bone. Five minutes
after the tissue injury, a controlled hemorrhage of 35% of the estimated total
blood volume was performed over 9 min 40 s via the femoral arterial cannula,
using a computer-controlled pump (Masterflex L/S model 7550-17; Cole Palmer
Instrument Company, Chicago, Ill). The rate of bleeding reduced exponentially
as the hemorrhage progressed to mimic the rate of hemorrhage from a major
arterial lesion. For blood volume and bleeding rate equations, see Garner et al.
and Stern et al. (21, 22).
Shock phase—Following hemorrhage, the animals underwent a 30-min
shock period during which a capped volume of 0.9% saline (500 mL maximum)
was administered as necessary to maintain a target systolic arterial blood pressure
(SBP) of 60 mmHg, reflecting an aspect of current clinical practice by combat
medical technicians (19). In addition, this was found to be necessary in a pilot
phase to avoid mortality in some animals. The practice was standardized by
applying a predefined and clinically relevant target to all animals. There were
no significant differences in the volumes of saline given in the three groups in
this phase of the study (P = 0.3450), which are shown in Figure 10. Resuscitation
infusions were warmed to 37-C and administered at a rate of 200 mL/min
(Belmont Rapid Infuser; Belmont Instrument Corporation, Billerica, Mass).
Prehospital evacuation phase—The next phase of the protocol represented
a 60-min prehospital evacuation phase. Warmed resuscitation fluid was admin-
istered according to the relevant protocol, with a final target SBP of 80 mmHg
in each group. Group 1 (n = 9) was given aliquots of 0.9% saline (representing
standard of care) to attain and maintain the target SBP, whereas group 2 (n = 9)
received PRBCs and FFP (1:1 ratio, PRBCs and FFP given simultaneously), and
group 3 (n = 6) was given PRBCs only. The volume of blood products in the
prehospital phase was capped at 4 U (4  450 mL approximately) per animal
(2 U PRBCs and 2 U FFP in group 2, and 4 U PRBCs in group 3, respectively,
reflecting current military and civilian prehospital emerging practice in the
United Kingdom). Once the maximum amount of blood product had been
used, resuscitation continued to the same pressure target using 0.9% saline for
the reminder of the prehospital evacuation phase. All infusion volumes were
measured accurately.
In-hospital phase—The in-hospital phase represented more aggressive re-
suscitation to a normotensive target (SBP 110 mmHg) using PRBCs:FFP (1:1)
in all groups. Supplementary oxygen (minimum FIO2 0.3) was given and titrated
to attain an arterial oxygen saturation (SaO2) of 98%. Because of the limitations
of the blood bank, the total amount of PRBCs:FFP used in any one animal was
capped at 6 U of each product (in addition to the PRBCs used during the
prehospital phase in group 3). Once the total permissible amount of PRBCs:FFP
had been given, resuscitation continued to the same pressure target using 0.9%
saline in all groups. In practice, few animals received saline in the in-hospital
phase (three of nine in group 1; two of nine in group 2; none of six in group 3;
Fig. 10). All animals in this study survived to the end of the protocol.
Sampling and measurements
Cardiovascular and paired arterial and mixed venous blood gas measure-
ments were made before and after injury/hemorrhage, after 15- and 30-min
shock, and at 30-min intervals during the prehospital resuscitation phase and
in-hospital resuscitation phases. Blood samples for assessment of clotting were
also taken at these timepoints.
Coagulation assays
Thromboelastography—Thromboelastography using a TEG 5000 Hemo-
stasis Analyzer (Haemonetics Ltd, Coventry, UK) was performed on fresh,
uncitrated whole blood. Arterial blood was taken from the femoral cannula and
analyzed immediately using dilute Innovin (1:50,887 dilution Dade Innovin;
Dade Behring, marketed by System UK Ltd, Milton Keynes, UK) as the
initiator (23). All TEG analyses were performed in triplicate at 37-C.
Prothrombin and activated partial thromboplastin times—Arterial blood
samples were taken into citrated Vacutainers (9NC 0.105 M Vacutainer
367691; Becton Dickinson, Oxford, UK) and centrifuged at 1,500g for 10 min.
The plasma was separated and stored at j80-C for determination of prothrom-
bin time (PT) and activated partial thromboplastin time (aPTT) by turbidometry
and fibrinogen concentration (Clauss method) using an ACL Elite analyzer
(Instrumentation Laboratories).
Study endpoints
The primary endpoint of the study was the clotting status assessed using
TEG after 30 min of in-hospital resuscitation. Secondary endpoints included
clotting status throughout the study and physiological status, in particular
degree of shock assessed by measuring actual base excess (ABE) and arterial
lactate and volumes of fluids used to attain the pressure-driven resusci-
tation targets.
At the end of the study, all animals were killed humanely using a lethal
overdose of sodium pentobarbitone (Euthatal; Merial Animal Health Ltd,
Harlow, Essex, UK) given intravenously.
Statistical analysis
All data are presented as mean T SEM unless indicated otherwise. Data
were assessed for normality and subjected to transformation if necessary. Time
series data were analyzed using 2-way analysis of variance (ANOVA) with re-
peated measures over time. Single timepoint analyses were made using 1-way
ANOVA with Fisher comparison of means for planned between-group comparisons.
Where it was not possible to conduct a parametric analysis, a Kruskal-Wallis
FIG. 1. Experimental protocol commencing approximately 1 h after the end of surgery showing the phases of the experimental protocol and
corresponding clinical phases for three groups of animals (treatment groups 1Y3 that diverge during the simulated evacuation phase where casualties
may be treated by the Medical Emergency Response Teams to receive expert medical attention, Expert Med before arrival at a field hospital, R3). In-
hospital (In-Hosp) phase divided into early and later surgical and postsurgical separated by assessment of primary outcome (clotting using TEG), treatment
identical in both in-hospital phases. BV indicates total estimated blood volume; Sal, saline. Ratios indicate ratio of PRBCs to FFP and indicates capped amount in
units (approximately 450 mL) of each constituent.
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multiple-comparisons test was used followed by Dunn test for planed
between-group comparisons. Any other tests are indicated in the text. Statisti-
cal analysis was performed using NCSS Statistical Software (NCSS, LLC,
East Kaysville, Utah). In all cases, a significance level of P G 0.05 (two-tailed)
was used.
RESULTS
All animals survived to the end of the study. Baseline (preinjury)
values are shown in Table 1. There were no significant differ-
ences between groups in the initial parameters except for body
temperature; although the difference between groups was statis-
tically significant, they are unlikely to be of physiological con-
sequence. Body temperature did not change significantly during
the course of the study (P = 0.3560).
Cardiovascular effects of tissue injury, hemorrhage,
and resuscitation
Tissue injury and hemorrhage led to a significant fall in arte-
rial blood pressure and cardiac index in all groups (P G 0.001).
There were no significant differences in the cardiovascular
response to hemorrhage between groups (P = 0.243; Fig. 2).
Systolic arterial blood pressure was thereafter maintained at
the relevant target for each phase of the protocol (Fig. 1). The
targets were attained in all groups, resulting in significant ele-
vations in blood pressure between phases (P G 0.001; Fig. 2).
Effects on clotting
Thromboelastography—The effect of the prehospital treat-
ments on the primary outcome of the study is summarized in
Table 2. At the onset of the in-hospital phase (after 60 min of
resuscitation), there were significant differences between groups.
This was due to group 1 (that had hitherto received 0.9% saline
only in the prehospital phase) displaying markedly elevated R
and K times compared with both groups 2 and 3. There were no
significant differences between groups 2 and 3. A similar situa-
tion was still present 30 min into the in-hospital phase, which
was the primary outcome of this study.
Time series data for the whole study showing overall
changes in coagulation are shown in Figure 3. Combined in-
jury and hemorrhage led to a small reduction in R and K times
(P = 0.0661 and P = 0.0182, respectively). There were no sig-
nificant differences between groups during the entire baseline,
injury/hemorrhage, and shock phases for either R or K times
(P = 0.6566 and P = 0.6977, respectively; Fig. 3). During the
prehospital phase, there were very marked alterations in both
R and K times leading to significant differences between groups
(P = 0.0098 and P = 0.0027). By the end of the prehospital
phase (60 min after the start of resuscitation), there was a clear,
significant difference between groups in both R and K times
(P = 0.006 and P = 0.002, respectively; Figure 3 and Table 2).
Overall, during the in-hospital phase, there were significant
differences between groups in R and K times (Fig. 3 and Table 2),
significant changes over time (P = 0.0019 and P = 0.0451), and
significant differences in patterns of response between groups
(P G 0.0001 and P = 0.0027). By 150 min after the onset of
resuscitation (90 min of in-hospital resuscitation), both R and K
times had recovered in group 1 to levels that were not signifi-
cantly different to those seen in the other two treatment groups
(P = 0.079 and P = 0.243). Therefore, group 1 developed a
coagulopathy that was apparent during the first hour of in-
hospital resuscitation with PRBCs:FFP and subsequently
resolved. By contrast, clotting in both groups 2 and 3 was
stable throughout.
TABLE 1. Initial values of physiological data and body weights
Group 1 Group 2 Group 3 P
No. animals 9 9 6
PaO2, kPa 8.9 T 0.1 9.2 T 0.2 8.4 T 0.4 0.101
PaCO2, kPa 6.6 T 0.2 6.6 T 0.2 6.8 T 0.2 0.805
Art pH 7.44 T 0.01 7.43 T 0.01 7.44 T 0.01 0.496
Hct, % 40.8 T 0.6 41.9 T 0.9 41.8 T 0.7 0.481
Fibrinogen, g/L 2.6 T 01 2.3 T 0.1 2.6 T 0.2 0.171
Body temperature, -C 39.1 (0.4) 38.8 (0.8) 38.2 (1.2) 0.030*
Body weight, kg 51.0 (4.5) 53.0 (6.0) 53.0 (4.5) 0.891*
Body weights and initial values of arterial oxygen and carbon dioxide
tensions (PaO2 and PaCO2) and pH (Art pH), hematocrit (Hct), and body
temperature.
P value for difference between groups.
*Comparison performed using Kruskal-Wallis one-way ANOVA because
data were not normally distributed. Values are mean T SEM or median
(interquartile range).
FIG. 2. Effects of issue injury and hemorrhage, followed by a shock phase (Sh), prehospital hypotensive resuscitation phase (Pre-Hosp), and in-
hospital normotensive resuscitation phase (In-Hosp). Treatment groups differed in the fluid used for resuscitation during Pre-Hosp; group 1 (n = 9) received
0.9% saline, group 2 (n = 9) received 1:1 PRBCs and FFP, and group 3 (n = 6) received PRBCs without FFP. All groups received PRBCs:FFP (1:1) during the in-
hospital phase. The first three datapoints represent, respectively, baseline value followed immediately before and immediately after tissue injury and hemor-
rhage. Systolic and mean arterial blood pressures (SBP and MBP) and cardiac index (CI). Mean values T SEM.
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In the model used in this study, clot strength, assessed using
TEG maximum amplitude (MA; Fig. 3), showed a significant
increase during the injury/hemorrhage and shock phase (P =
0.014), but no difference between groups (P = 0.319). Subse-
quently, there was a small fall in MA, but no change indicative
of a coagulopathy in any group. No significant difference in
MA was found between groups at any time during the study.
Activated partial thromboplastin time and PT—Activated
partial thromboplastin time (Fig. 4) showed a similar pattern
to that reported for TEG R and K times. However, there were
significant differences in baseline aPTT between groups (P =
0.023); therefore, all subsequent analyses were performed by
determining changes from baseline to eliminate the effects of
baseline differences. During the baseline, injury/hemorrhage,
and shock phases, there were no significant differences between
groups (P = 0.9655). However, during the prehospital phase, there
was a significant change in aPTT (P = 0.0011), and a different
pattern between groups (P = 0.0018), with a marked increase in
aPTT in group 1, but not in the other two groups. By the in-
hospital phase (60 min from the start of resuscitation), aPTT
was higher in group 1, although this did not attain statistical sig-
nificance (P = 0.0818). Overall, there was a significant change
in aPTT over time during the in-hospital phase (P = 0.0002), and
again a different pattern between groups (P = 0.0466), with aPTT
in group 1 recovering toward levels seen in the other two groups
in the latter part of the in-hospital resuscitation phase.
The initial changes in PT were similar to those seen in aPTT
(shock and prehospital resuscitation phases); however, the
pattern then differed markedly in the in-hospital phase (Fig. 4).
During the baseline, injury/hemorrhage, and shock phase,
there was no difference in PT between groups (P = 0.2038),
although there was a small but statistically significant change
over time (P G 0.001). During the prehospital resuscitation
phase, there were significant differences between treatment
groups (P = 0.0054) and over time (P G 0.0001) as PT rose in
group 1, but not in the other two groups (P = 0.0011). By the
end of the prehospital phase, PT was significantly higher in
group 1 compared with groups 2 and 3 (P = 0005 and P =
0.0251). During the in-hospital phase, the significant differ-
ence between groups persisted (P = 0.0203). There was a
change in PT over time in the in-hospital phase (P G 0.001),
but no difference in pattern between groups (P = 0.3057).
Therefore, PT data showed a coagulopathy developing in the
group 1 when compared with group 2 during the prehospital
and early in-hospital resuscitation phases, but in contrast to the
other parameters (TEG and aPTT), this did not resolve in any
group during the latter part of the in-hospital phase (Fig. 4).
Fibrinogen levels and platelet count—There were no sig-
nificant differences in baseline fibrinogen levels between
groups (P = 0.172). During the injury/hemorrhage and shock
phases, there was a statistically significant fall in fibrinogen
levels (P = 0.001) without any differences between groups
TABLE 2. Primary outcome measure (clotting assessed by TEG after 90 min of resuscitation, corresponding to 30 min in-hospital)
Timepoint
TEG
parameter
Group 1
prehospital
saline
Group 2
prehospital
PRBCs:FFP
Group 3
prehospital
PRBCs alone
Statistical P
Between groups G1 vs. G2 G1 vs. G3 G2 vs. G3
60-min Resuscitation
(immediate in-hospital)
R, min 40.4 T 8.8 17.4 T 2.9 14.7 T 1.9 0.006 0.004 0.007 0.851
K, min 17.1 T 3.4 6.8 T 1.5 5.8 T 0.9 0.002 0.002 0.003 0.900
MA, mm 68.1 T 2.6 65.8 T 2.1 64.7 T 1.5 0.587 NA NA NA
90-min Resuscitation
(30 min in-hospital)
R, min 38.3 T 10.7 16.9 T 2.4 14.5 T 1.7 0.025 0.017 0.022 0.887
K, min 19.1 T 6.2 6.1 T 1.5 5.6 T 0.9 0.035* G0.05 G0.05 90.05
MA, mm 60.8 T 5.0 64.8 T 2.0 65.1 T 1.5 0.586 NA NA NA
Data are also shown for clotting after 60 min of resuscitation (corresponding to arrival at hospital).
*Comparison performed using Kruskal-Wallis one-way ANOVA on ranks followed by Dunn comparisons because the data were resistant to transfor-
mation and could not be analyzed using a parametric test.
NA indicates further comparisons not applicable because there is no overall difference between groups. Values are mean T SEM.
FIG. 3. Effects of tissue injury, hemorrhagic shock, and resuscitation on TEG R time (clot initiation), K time (clot dynamics), and MA (clot strength)
in three treatment groups. For more details, see legend to Figures 1 and 2. Mean values T SEM.
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(P = 0.99; Fig. 5), although this is unlikely to be of clinical
significance. During the prehospital phase, fibrinogen fell fur-
ther in all groups (P = 0.002), and again there were no sta-
tistically significant differences between groups (P = 0.154).
By the end of prehospital resuscitation, fibrinogen was lowest
in group 1, although this was not statistically different from
the other groups (Fig. 5). The lowest mean level attained in
group 1 (1.50 T 0.12 g/L) was only slightly below the 95%
reference range for this strain of pigs (1.77Y3.36 g/L, n = 147).
(Data based on samples taken after minimal surgery [induction
of anesthesia and insertion of carotid cannula] in Large White
pigs of similar age that contributed to this and other studies in
our laboratory. Data distribution was normalized with a 1/square
root transformation prior to determining the reference range.)
Seven of nine pigs in group 1 were below the reference range at
the end of prehospital resuscitation compared with four of nine
in group 2 and four of six in group 3.
The fall in fibrinogen levels at the end of the prehospital
phase was due to more than the hemodilution associated with
resuscitation. Changes in hematocrit (Fig. 5) were taken as a
marker of hemodilution during the prehospital phase in group
1 because there was no external gain or loss of red blood cells
during this phase in group 1. The ratio of the proportional fall
in fibrinogen levels from baseline to the proportional fall in
hematocrit from baseline should be 1 if the reduction in fibrin-
ogen levels is in proportion to hemodilution and below one if
there is additional loss of fibrinogen. The ratio at the end of the
prehospital phase in group 1 was 0.84 T 0.04, which was sig-
nificantly below 1 (P = 0.009, one-sample t test), suggesting loss
of fibrinogen over and above the effects of hemodilution. Dur-
ing the subsequent in-hospital phase, there was a small elevation
in fibrinogen levels that was statistically significant (P = 0.005),
but no significant difference between groups (P = 0.332).
There was a fall in platelet count in all groups over the course of
the study, which attained statistical significance (P = 0.001;
Fig. 5). However, there was no statistically significant dif-
ference between groups at any stage in the study (P = 0.423).
Blood chemistry and oxygen transport
Arterial base excess, lactate, and shock—The degree of
shock was evaluated by measuring changes in arterial base
excess and lactate levels (Fig. 6). During hemorrhagic shock,
there was a marked clinically and statistically significant fall
in arterial ABE (P G 0.0001) and a rise in arterial lactate (P G
0.0001), without any significant difference between groups
(P = 0.7787 and P = 0.8300, respectively). This was associated
with a significant elevation in whole-body oxygen extraction
ratio (OER; Fig. 7) from normal preinjury baseline levels in
the range 0.25 to 0.30 to theoretical maximal levels in the
range 0.78 to 0.80 (P G 0.0001). There were no significant
differences in OER between groups (P = 0.254; Fig. 7). The
high levels of OER persisted in all groups throughout the
prehospital phase, whereas base excess continued to fall and
lactate rose (P G 0001 and P G 0.0001). There was a trend for
FIG. 4. Effects of tissue injury, hemorrhagic shock, and resuscitation on aPTT and PT in three treatment groups. For more details, see legend to
Figures 1 and 2. Mean values T SEM.
FIG. 5. Effects of tissue injury, hemorrhagic shock, and resuscitation on fibrinogen levels, platelet count (Plt), and hematocrit (Hct) in three
treatment groups. For more details, see legend to Figures 1 and 2. Mean values T SEM.
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ABE to reach its nadir and lactate to reach its peak in group 2,
whereas these variables continued to deteriorate in the other
two groups; however, there were no significant differences
between groups for either ABE (P = 0.3937) or lactate (P =
0.4330). Throughout the in-hospital phase, the trend for less
negative ABE and lower lactate in group 2 persisted, although
again this was not statistically significant (P = 0.1483 and P =
0.4720, respectively).
The cumulative burden of shock was evaluated by determin-
ing the area under the ABE curve for each individual pig (Fig. 8).
The area under the curve was significantly less in group 2
when compared with group 1 (P = 0.0380, Mann-Whitney
U test). It was not possible to compare group 3 to the other
two groups because of the difference in distribution of data in
group 3 that proved resistant to transformation and precluded
statistical comparison.
Oxygen transport—Hematocrit fell significantly in all groups
during the shock phase (P G 0.0001), with no difference be-
tween groups (P = 0.1420). Once the treatment groups diverged
in the prehospital phase, differences between groups became
significant (P G 0.0001), with hematocrit rising in group 3 and
falling in the other two groups. The greatest fall was in group 1.
Hematocrit remained significantly higher in group 3 compared
with the other two groups for the reminder of the study, whereas
groups 1 and 2 converged during the in-hospital phase. Arterial
oxygen content followed the same pattern (Fig. 7). There was a
significant fall in mixed venous oxygen content during the
shock and prehospital phases (P G 0.0001), followed by an
increase during the in-hospital phase (Fig. 7, P G 0.0001).
There were no differences between groups in mixed venous
oxygen content at any stage in the study (P = 0.099).
Fluid administration
The cumulative volumes of combined fluid given during the
study are shown in Figure 9. There was no significant differ-
ence between groups in the volume of saline required during
the shock phase (Fig. 10, P = 0.3450). Overall, group 1 re-
quired a significantly greater volume of combined fluids dur-
ing the prehospital phase and over the course of the study (P =
0.0005 and P = 0.0067; Fig. 10). The increased combined fluid
requirement in group 1 was due to a significantly greater vol-
ume of saline used in this group compared with the other two
(P = 0.0001, Kruskal-Wallis multiple-comparisons test). Most
of this saline was administered in the prehospital phase. There
was no overall difference in the amount of PRBCs:FFP re-
quired between the groups (Fig. 10, P = 0.2748).
DISCUSSION
In this study, we modeled severely injured casualties who
require resuscitation to sustain life en route to hospital. The
model incorporated tissue injury, controlled hemorrhage, and
hemorrhagic shock followed by resuscitation to clinically rel-
evant targets, representing prehospital and in-hospital phases
FIG. 6. Effects of tissue injury, hemorrhagic shock, and resuscitation on arterial base excess (ABE) and lactate (Art Lactate) in three treatment
groups. For more details, see legend to Figures 1 and 2. Mean values T SEM.
FIG. 7. Effects of tissue injury, hemorrhagic shock, and resuscitation on OER, arterial oxygen content (CaO2), and mixed venous oxygen content
(CvO2) in three treatment groups. For more details, see legend to Figures 1 and 2. Mean values T SEM.
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of treatment, which resulted in 100% survival to the end of the
study in all groups presented in this report. The principal
finding is that use of blood products for Bprehospital[ re-
suscitation attenuated the coagulopathy that developed in the
control group (group 1), which was given 0.9% saline only in
the prehospital phase. A surprising finding was that the use of
PRBCs alone in the prehospital phase was as effective as
PRBCs:FFP (1:1 ratio) in avoiding ATC in this model. This
finding is consistent with the concept that it is tissue hypo-
perfusion and possibly reduced oxygen delivery that are the early
drivers of ATC (24, 25). More aggressive Bin-hospital[ resus-
citation with PRBCs:FFP resolved the coagulopathy in group 1
after a delay of approximately 60 min, and by 90 min in-hospital
the coagulation parameters had converged in all the groups. In
our model, therefore, prehospital use of blood products does
confer benefit extending into relevant in-hospital phases, even
when aggressive resuscitation strategies are used from the
outset in the in-hospital phase.
Saline 0.9% was chosen as the control limb in this study
principally because it is the most commonly used prehospital
resuscitation fluid by UK forces and is currently in widespread
use in civilian practice despite concerns expressed by some
about its Bunphysiological[ effects. The purpose of this study
was to compare emerging treatment with current clinical stan-
dards; hence, colloid solutions were not used simply because
they are not in widespread prehospital use for trauma casualties.
This is despite their having the scientific merit of more closely
resembling plasma with respect to retention in the vascular
space. Alternatives such as starch solutions (e.g., Hextend) were
not used in the present study because they are used less com-
monly in the prehospital arena (e.g., 36% of US casualties in
Iraq compared with 64% given crystalloid [26]), and in the
case of starch solutions, they may impair coagulation by in-
ducing additional hemodilution and by direct interaction with
clotting mechanisms (26).
Fibrinogen was found to decrease in all groups during shock
and subsequent resuscitation, with the greatest fall being seen
in group 1. It is difficult to determine the contribution of this
fall in fibrinogen levels to the coagulopathy developed in
group 1 during prehospital resuscitation. At the end of the
prehospital phase, the fibrinogen level in group 1 was slightly
below the 95% reference range for this strain of pigs; how-
ever, this is in the context of a shock state and reduced
platelet count, which may have accentuated the effects of the
lowered fibrinogen. In the other two (blood products) groups,
fibrinogen levels fell to mean levels that were slightly above
the lower 95% reference range for the pigs. The most likely
conclusion is that the fall in fibrinogen levels may have con-
tributed to the coagulopathy seen in group 1, but it is unlikely
to be the sole or even major contributor to the difference
between groups.
Secondary findings relate to changes in physiological state
and volumes of fluid used for resuscitation. All groups developed
a significant degree of shock during the prehospital phases, seen
as a marked fall in base excess and elevated lactate levels.
Prehospital PRBCs:FFP (group 2) appeared to afford the greatest
protection against shock, which is counterintuitive because,
predictably, arterial oxygen content was highest in group 3
(given prehospital PRBCs alone). Unfortunately, it was not
possible to compare statistically the cumulative burden of shock
between groups 2 and 3 because of the different distribution in
the two groups, but the overall levels of both base excess and
lactate in group 3 are nearer group 1 than group 2 (Fig. 6). It is
clear that oxygen extraction was maximal in all of the groups
during the prehospital phase (equally high OER and low mixed
venous oxygen content in all groups), suggesting that the low
blood flow state inherent in hypotensive resuscitation was the
limiting factor. It is possible that the better performance of
PRBCs:FFP may reflect a beneficial effect of the plasma on
the microvasculature, possibly via an action on the endothelium
and/or glycocalyx (27Y29), which optimized local control and
oxygen delivery. In addition, the buffering capacity of FFP may
also have played a part in reducing the acidosis.
The overall volume of fluid needed for resuscitation was
considerably less in the groups given prehospital blood prod-
ucts. This difference was due to a much greater volume of saline
needed in group 1, and the magnitude is likely to be of clinical
significance especially given the emerging concerns regard-
ing the deleterious effect of crystalloid on the vascular endo-
thelium and inflammatory responses (30). In a military context,
the reduction in volume of prehospital fluid requirement is
FIG. 8. Cumulative area under the arterial base excess curve for each
individual animal (AUC). Area integrated between start of resuscitation
(beginning of prehospital resuscitation) and end of the in-hospital phase.
Negative values indicate shock. Data shown for each individual animal in
three treatment groups, and medians and interquartile ranges.
FIG. 9. Cumulative total of combined resuscitation fluid infusion
(0.9% saline, PRBCs:FFP, and PRBCs alone) in three treatment groups.
For more details, see legend to Figures 1 and 2. Mean values T SEM.
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likely to have a logistical benefit, although the cooling required
for blood products to some degree negates this. Future studies
will need to evaluate products that confer the physiological
benefits of PRBCs and FFP without the logistical burden of
refrigeration. Lyophilized plasma has already shown promise in
both animal studies (31) and emerging clinical practice (32Y34).
Finally, it was reassuring that the early administration of blood
products did not increase the overall demand for these products
and is therefore unlikely to result in a greater overall burden on
blood banks.
The results of our study are in broad agreement with a recent
observational clinical study that compared prehospital trans-
port platforms, one of which used plasma and red blood cells
(1:1), and the other(s) used crystalloids (35). This observa-
tional study reported a statistically significant improvement in
physiological status (base excess, j3 vs. j4 mM) and a clear
reduction in volumes of prehospital fluids needed (35). How-
ever, there was no difference in measured clotting status
between groups in this study (35). One possible explanation
for this is that although the patients were severely injured based
on the Injury Severity Scores, the degree of underlying shock
was not great, in contrast to our study where there was a more
profound degree of shock. Although our study shows that
prehospital PRBCs alone was also effective in reducing
coagulopathy, these results should not be taken to contra-
dict the clinical trials (such as the PROPPR trial [36]) that
show high ratios of plasma to red blood cells provide benefit
such as improved hemostasis. The most likely explanation for
the beneficial effect of PRBCs alone in our study rests with
the evolving mechanism underpinning ATC (37), such that
the very early phase may indeed be responsive to improved
perfusion and oxygen delivery, although the contribution of
any residual plasma in our PRBCs cannot be ruled out.
In any experimental study, the nature of the model used
defines the limitations of the conclusions. In this study, we
were attempting to model a severely injured battlefield casu-
alty with a significant burden of injury and hemorrhagic shock,
who would initially receive very limited resuscitation (19, 38, 39)
once hemorrhage has been arrested, prior to evacuation to a
hospital. Our model therefore incorporated elements of sig-
nificant tissue injury and hemorrhagic shock (with associated
hypoperfusion) as suggested by Frith et al. (40), followed by
clinically relevant resuscitation, all in the correct chronological
sequence. A 1-h evacuation timeline was selected because it is
broadly representative of recent military (38, 41) and civilian
evacuation timelines in the United Kingdom and Europe (9, 10)
and United States (35) during which hypotensive resuscita-
tion is practiced (18, 19), although shorter timelines have
been reported in a number of US studies (24, 25). The end-
point of resuscitation was a pressure-driven target because
this is all that there is currently available in the prehospital
military setting, i.e., administration of fluid to attain a palpable
carotid (corresponding approximately to a SBP of 60 mmHg)
or radial (SBP 80 mmHg) pulses. To mimic the current clin-
ical practice, fluid was therefore administered only if arterial
blood pressure fell below the target corresponding to loss of
carotid or radial pulses (depending on the phase of the pro-
tocol, the most cautious in the shock phase). On entering the
in-hospital phase of the model, a more aggressive resuscita-
tion to a normotensive target was adopted using PRBCs:FFP
(1:1 ratio), representing current best clinical practice. Com-
parison of these prehospital treatment groups therefore allowed
an evaluation of the impact of prehospital blood products in the
context of a severely injured casualty given the best treatment
immediately on arrival in hospital.
The resuscitation was conducted to defined, clinically rele-
vant, hypotensive pressure targets in the prehospital phases.
This was designed to limit the volume of fluid given to the
minimum required to sustain life. In the model development
phase, failure to provide this fluid was not compatible with
survival, emphasizing the severity of the injury/shock model
presented here. In the control group (group 1), saline was used
exclusively in the prehospital phase because this is still in
widespread clinical use. This led to a degree of hemodilu-
tion as seen by the fall in hematocrit. However, this degree
of hemodilution is a valid part of the overall model because
it represents the dilution inherent in prehospital resuscita-
tion using crystalloids (the old/current standard of care). To
place the hemodilution in the present study into the context
of other models of injury, the volume of 0.9% saline used
in group 1 in this study represents approximately 0.68 of
the remaining blood volume at the end of the hemorrhage.
By contrast, an established model published by Cho et al. (42)
administered a volume of saline corresponding to approximately
4.5 times the end hemorrhage blood volume. It is therefore
likely that although the coagulopathy seen in the present study
FIG. 10. Total volume of component fluids given in each phase of the protocol (shock, prehospital resuscitation, and in-hospital resuscitation) in
three treatment groups. Mean values T SEM.
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may have an element of dilution, it is not an overwhelming
degree of dilution.
It is therefore very unlikely that all of the coagulopathy
seen in the present study was due to hemodilution. However,
it is important to acknowledge that a dilutional element is
probably also present, but the volume of fluid given was kept
to a minimum compatible with survival by using clinically rel-
evant resuscitation targets. The results of this study are therefore
relevant to a situation where a severely injured casualty demands
a limited degree of resuscitation to sustain life during evacuation
to a hospital and is therefore relevant for military battlefield
casualties (19) and some civilian trauma victims where fluid is
given in the evacuation phase (10).
In the present study, we utilized a controlled hemorrhage
rather than uncontrolled blood loss, which is important to ac-
knowledge. The results of the present study are therefore most
relevant for a casualty in whom the majority of the hemorrhage
has been controlled at an early stage either by the patient_s own
Bfirst clot[ or by the effective deployment of the GC9ABC
paradigm which targets uncontrolled bleeding from major ves-
sels (43). However, any small vessel bleeding from the exten-
sive tissue contusion that represented the tissue injury element
was not controlled externally. Because this represents a large
volume of tissue (surface area of damaged vasculature), it may
represent a greater potential sink for hemostatic factors than, for
example, the uncompressed grade IV liver injury we used in the
past as a model to assess potential rebleeding in new resusci-
tation strategies (44). It is impossible to quantify the impact of
this tissue injury on the overall coagulopathy and response to
treatment in the present study. By contrast to our model, Sondeen
et al. (26) have modeled an uncontrolled truncal hemorrhage
by incorporation of a splenic injury. In further contrast to our
model, the postinjury resuscitation essentially represents a pro-
longed (5 h) prehospital phase with limited fluid resuscitation
and consequently significant mortality. Both models are valid
representations of different scenarios. The results of the two
studies are in broad agreement. Use of blood products, even
when the ratio of PRBCss to plasma is high, obviated mea-
sured clotting abnormalities compared with resuscitation with
a starch solution (Hextend) and also reduced blood loss com-
pared with both starch and crystalloid (Ringer_s lactate) solutions.
It is of interest in the latter study (26) that use of crystalloid
was not associated with clotting abnormalities when assessed
with TEG and only transiently (one early timepoint) associated
with increased PT. The authors (26) suggest that this may be due
in part to greater hemodilution and/or direct interference with
clotting mechanisms induced by the starch solution.
Thromboelastography was chosen as the primary method of
assessing clotting in this study because it is a whole-blood test
and is viewed as being superior to Bconventional tests[ (PT or
aPTT) in studies in pigs (45). Reassuringly, however, an aPTT
gave a similar overall pattern (although not statistically signifi-
cant) to that seen with TEG. The initial coagulopathy was also
seen when PT was used, although the reversal of coagulopathy
seen in the in-hospital phase with both TEG and aPTT was
not seen with PT. We have no explanation for this difference
between tests, although it has been suggested that aPTT (rather
than PT) is becoming increasingly recognized as the better
assessment in trauma coagulopathy (T. Wolley, personal com-
munication oral, April 2015). The present study has a number
of limitations. It is an animal-based study, and differences as
well as similarities to the human response need to be acknowl-
edged. The hemodynamic response to trauma is broadly simi-
lar between humans and pigs, and the splenectomy performed
in our study removes the capacity to autotransfuse splenic blood
that can occur in pigs but not humans; hence, the pig is a widely
accepted model of human trauma. Although there are simi-
larities in clotting between pigs and humans, there are also
important differences, e.g., uninjured pigs are hypercoagulable
compared with humans. These differences are likely to be of
importance when assessing some of the specific component
therapies, but they do not obviate the general conclusions re-
garding patterns of changes described in this report. Caution must
always be exercised when comparing between species; patterns
of response rather than absolute numerical values should be
compared. It is notable in the present study that the coagu-
lopathy was characterized on the basis of clot initiation and
dynamics, but no change was seen in clot strength despite a
marked coagulopathy developing based on the other parame-
ters. The solution to these general limitations of animal-based
studies is to triangulate results between species and models and
always make comparisons to humans whenever data are available.
In conclusion, this study provides evidence that use of pre-
hospital blood products confers advantage compared with the
old standard of care (limited crystalloid administration) and
supports a treatment strategy that was started pragmatically by
clinicians (MERT) in Afghanistan. If FFP is not available, then
PRBCs alone has a clear benefit over saline. Further studies
addressing longer prehospital timelines may be needed for
future military operations in austere environments. The use of
components such as fibrinogen and other products that do not
require refrigeration needs to be examined to reduce the logis-
tical burden associated with prehospital deployment of these
important products.
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